Pfizer Invests In Potential New Drug Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Aptamer therapeutics act like biologics but are chemically synthesized, according to Pfizer collaborator Archemix.
You may also be interested in...
Roche Keeps Shopping: Mirus Acquisition Bolsters RNAi Portfolio
Firm will pay $125 million for access to Wisconsin-based Mirus’ Dynamic PolyConjugates technology.
Roche Keeps Shopping: Mirus Acquisition Bolsters RNAi Portfolio
Firm will pay $125 million for access to Wisconsin-based Mirus’ Dynamic PolyConjugates technology.
Isis Sees A “Fit” With Archemix In Developing Novel Oligonucleotide-Based Drugs
Firms enter strategic alliance that provides Archemix access to four hundred Isis patents for developing proprietary aptamer therapeutics.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: